To evaluate whether patients with persistent muscle-invasive bladder cancer (MIBC) after undergoing neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) have worse overall survival (OS) and cancer-specific survival (CSS) than patients with similar pathology who undergo RC alone.
Introduction
Neoadjuvant chemotherapy (NAC) with cisplatin-based combination therapy prior to radical cystectomy (RC) is currently recommended to treat muscle-invasive bladder cancer (MIBC) [1] . This recommendation is based on an absolute survival benefit of 5% at 5 years in patients who underwent NAC [2] . NAC is not without risk, however, and the appropriate selection of patients is necessary.
Studies with and without NAC have shown a correlation between pathological downstaging at the time of RC and higher rates of survival [3] [4] [5] [6] [7] . According to a post hoc analysis based on the Nordic Cystectomy trials 1 and 2, downstaging by NAC is a surrogate marker for longer survival after RC [5] . The same analysis showed that patients with tumours that were not downstaged by NAC had a lower survival rate at 5 years than patients who did not undergo NAC, although the difference was not statistically significant [5] . A recent stage-matched analysis found that patients with residual cancer at the time of RC who underwent NAC had worse oncological outcomes than patients who underwent RC alone [6] .
The survival benefit from NAC is less debated in patients whose tumours are downstaged to non-muscle-invasive disease (≤pT1) or to complete response (pT0). Based on this, our focus was on patients with persistent MIBC after RC.
We compared rates of death (from any cause and from cancer) in patients with persistent MIBC after NAC + RC with those in patients with MIBC at the same pathological stage who underwent RC alone.
Materials and Methods
After obtaining approval from our institutional review board, we searched the SEER-Medicare database for linked data on patients with bladder cancer with non-metastatic urothelial carcinoma (International Classification of Diseases for Oncology histology codes: 8120-8131), diagnosed in 2004 to 2011, who were treated with RC. We began our analysis at 2004 in order to better capture patients undergoing NAC with contemporary, platinum-based chemotherapy, based on the findings by Grossman et al. in 2003 [3] . We identified patients with ≥pT2N0M0 stage disease, and excluded patients with metastatic disease (N1-3, M1) and/or missing data. Exclusion details, procedure and chemotherapy codes, per Current Procedural Terminology, are available for review in Table S1 . Patients receiving chemotherapy after RC (adjuvant or salvage) were not excluded but were adjusted for in the Cox analysis.
Surveillance, Epidemiology and End Results (SEER)-Medicare staging is based on either clinical or pathological staging (from transurethral resection or RC). We included only patients who had pathological staging after RC. Currently, no standardized definition of non-responders to NAC exists, nor does any method to preemptively differentiate responders from non-responders [1, 8] ; however, previous studies have alluded to patients who undergo NAC for MIBC who have residual muscle-invasive disease (ypT2) as pathological nonresponders [8, 9] . Because both clinical and pathological staging data were not available uniformly for all patients in SEER-Medicare, we could not stratify patients based on the pathological response. As a surrogate, we evaluated patients who had persistent muscle-invasive disease at the time of RC based on the American Joint Committee on Cancer (AJCC) primary tumour, regional lymph node and distant metastasis (TNM) staging [10] . We defined NAC as chemotherapy administered <6 months before RC. Chemotherapy claims billed up to 60 days after RC were included within NAC. Information regarding the chemotherapy used is provided in Table S2 . We compared patients who received NAC + RC and had persistent muscle-invasive disease at RC with those with pathologically similar disease who underwent RC alone.
Statistical Analysis
We used summary statistics to describe patient and disease characteristics and, to evaluate any differences, we used the chi-squared test. We measured survival time from the time of diagnosis by transurethral resection of bladder tumour (TURBT) to either the patient's death or the end of our observation period (31 December 2012). The time from TURBT to RC in patients who received preoperative NAC vs that in patients who did not was compared using a t-test. Kaplan-Meier time-to-event analysis was used to estimate cancer-specific (CSS) and overall survival (OS), and the logrank test was applied to compare the characteristics of patients who underwent NAC + RC vs RC alone. CSS was defined as survival in the absence of other causes of death than cancer. The censoring event was the end of our observation period and the outcome of interest was the patient's survival or death.
To compare rates of death between patients with muscleinvasive disease after NAC + RC against similarly staged patients who underwent RC alone, we used Cox proportional hazard regression modelling. We adjusted for confounders, including age, sex, race, year of diagnosis, income, education, tumour stage, tumour grade, Charlson comorbidity index score, lymphadenectomy and post-RC chemotherapy. To assess comorbidities, we used the Klabunde modification of the Charlson comorbidity index [11] . For all statistical analysis, we used SAS version 9.3 (SAS Institute, Cary, NC, USA). All P values reported are two-sided; we considered a P value < 0.05 to be statistically significant.
We recognize that only 55% of patients in our study population received cisplatin-based chemotherapy. To mitigate this, we performed a sensitivity analysis comparing patients who received NAC + RC with cisplatin-based chemotherapy vs RC alone. Additionally, due to the significant difference in pathologic stage found between patients receiving NAC+RC vs RC alone (Table 1) , a subset analysis was performed stratifying patients based on stage.
To reduce the impact of treatment selection bias, adjustment of patient characteristics was performed with inverse probability of treatment weighting with propensity scoring [12] . Variables in the model predicting the probability of receiving NAC included age, sex, race, year of diagnosis, income, education, tumour stage, tumour grade and Charlson comorbidity index. The weight for each subject is equal to the stabilized inverse propensity score. Weighted and unweighted Kaplan-Meier time-to-event analysis was used to compare the OS and CSS after diagnosis in patients receiving NAC + RC vs RC alone. A weighted Cox proportional hazard regression model was also created to compare the OS and CSS after diagnosis in patients receiving NAC + RC vs RC alone.
We also conducted landmark analysis at 9 months after diagnosis to estimate the time-to-event probabilities in each group and to correct for immortal time bias [13] . The landmark was chosen as 9 months after diagnosis because >90% of the patients underwent their RC at this time. Patients who died before the landmark time point were removed. The OS was compared between the two groups using the Kaplan-Meier method.
Results
We identified 79 755 patients with bladder cancer with nonmetastatic urothelial cell carcinoma in the SEER-Medicare database. After exclusions, we analysed 4 709 who were treated with RC. Of these patients, 1 886 patients had stage ≥pT2N0M0. Of those, 1 505 underwent RC alone, while 381 underwent NAC + RC (Fig. 1) . Patient characteristics for our final study group are presented in Table 1 . The median (interquartile range) follow-up time was 25 (11-47) months. Chemotherapy data were available for 92% of patients undergoing NAC, of whom 55% (n = 192) received cisplatinbased chemotherapy and 36% (n = 125) received carboplatinbased chemotherapy, and the remaining patients received other or unknown type of chemotherapy (Table S2 ).
According to the propensity-weighted Kaplan-Meier analysis, the 5-year OS was improved among patients undergoing NAC + RC vs RC alone who had pT2-T4N0M0 after RC (43.5% vs 37.2%; P = 0.001 [ Fig. 2 Subset analysis showed an OS advantage in patients with organconfined (pT2N0M0) disease who had received NAC + RC: Kaplan-Meier analysis: 61.4% vs 51.3% (P = 0.04) and Cox analysis: HR 0.69 (95% CI 0.52-0.93; P = 0.01 [ Fig. 3 , Table 2 ]). However, while this OS benefit was seen in patients with nonorgan-confined disease (pT3-4N0M0) who received NAC+RC on Kaplan-Meier analysis (5-year survival 36% vs 26%; P = 0.01), the difference was no longer evident after adjusting for confounders with Cox analysis (HR 0.9 [95% CI 0.73-1.10]; P = 0.31 [ Fig. 4 Landmark analysis performed at 9 months after diagnosis with bladder cancer (the point at which 90% of patients had undergone RC) showed no difference in OS between patients with stage pT2-4N0M0 undergoing NAC + RC vs RC alone (P = 0.59 [ Fig. S1] ).
Discussion
We found that patients with persistent post-RC pathology showing pT2-T4N0M0 disease obtained OS benefit from NAC + RC; however, on subgroup analysis, this benefit was not apparent for those with non-organ-confined disease (pT3-T4N0M0; Table 2 , Fig. 2 ). Furthermore, there was no CSS benefit in patients who had persistent pT2-T4N0M0 disease after NAC + RC compared with those who underwent RC alone ( Table 2 , Fig. 2 ). These results are unchanged on sensitivity analysis evaluating patients who received cisplatin-based chemotherapy.
These results are consistent with previous studies showing that tumour downstaging (either by TURBT or NAC) was associated with significantly higher rates of recurrence-free survival and CSS [4] [5] [6] 14, 15] . For example, a retrospective analysis of 449 patients in the Nordic Cystectomy trials 1 and 2 found complete downstaging (AJCC stage 0, pT0N0M0) in 22.7% of patients who underwent NAC + RC [5] . In a subgroup analysis of those trials, patients with clinical AJCC stage III tumours that were downstaged to pT0, pT1 or pT2 derived the most significant benefit from NAC [5] ; however, that same subgroup analysis found no difference between those who were not downstaged by NAC vs the RC-alone group [5] .
We built on a recent report by Bhindi et al. [6] of 504 stagematched patients from a single institution who underwent NAC + RC (n = 180) vs RC alone (n = 324). That report found that patients who underwent NAC + RC and had residual urothelial carcinoma of the bladder at the time of RC had a higher rate of death from cancer (40% vs 59%; P = 0.003) and a lower OS rate (33% vs 48%; P = 0.02) than those who underwent RC alone [6] . At 5 years, the overall survival is 43.5% in the NAC+RC group and 37.2% in the RC alone group.
At 5 years, the cancer specific survival is 53.7% in the NAC+RC group and 58.4% in the RC alone group. Our findings contradict the findings of Bhindi et al. [6] , while supporting the results of a recent publication comparing pathological outcomes of patients downstaged by NAC vs TURBT prior to RC. The study compared patients with MIBC (T2) at time of TURBT who received complete pathological response (defined as T0N0) or partial pathological response (defined as pTa, pTis or pT1 and N0) or no response (T2) to either TURBT + NAC or TURBT alone prior to RC. The authors found that there was no significant difference in OS between patients who received NAC and those who did not, if patients did not achieve pathological response (P = 0.35) [15] . 
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At 5 years, the overall survival is 61.4% in the NAC+RC group and 51.3% in the RC alone group.
At 5 years, the cancer specific survival is 72.9% in the NAC+RC group and 73.3% in the RC alone group. It is recognized that patients with complete or partial response to NAC have improved survival compared with those who do not respond [9] . Based on this previous research and our present findings, there is concern that patients with residual or persistent muscle-invasive (pT2-T4) disease after NAC + RC may derive no benefit and have even worse CSS and OS than those undergoing RC alone [5, 6, 15] . In the present study, the lack of OS or CSS is most evident in patients with pT3-4N0M0 (non-organ-confined) disease.
The results of the present study suggest that patients with pT2N0M0 derive no CSS benefit from NAC + RC and those with pT3-4N0M0 disease have no OS or CSS benefit, which raises the question of whethter these patients should receive adjuvant treatment. The data for adjuvant chemotherapy after NAC + RC are not clear. A recent study of 705 patients found that those with non-organ-confined bladder cancer (pT3/pT4) at time of RC or node-positive disease at time of RC, who received NAC, had no benefit to adjuvant chemotherapy [16] . Currently, National Comprehensive Cancer Network recommendations for adjuvant treatment are for patients with pT3-pT4 disease or nodal disease [17] . There are limited trials and studies of patients with pT2N0M0 after NAC + RC undergoing adjuvant chemotherapy. Most ongoing immunotherapy trials using checkpoint inhibitors exclude patients with persistent pT2N0M0 disease after NAC + RC. The present data suggest that perhaps these patients should be considered for such trials or for adjuvant chemotherapy. Currently, one trial with adjuvant pembrolizumab is recruiting patients with persistent ≥pT2 after NAC (NCT03244384). Another trial using neoadjuvant atezolizumab with similar enrolment criteria recently completed accrual (NCT02951767).
New evidence shows clinical value in stratifying patients with persistent T2N0M0 disease after NAC into two categories: those with stable disease (clinical disease equal to post-RC pathological disease) vs progressors (post-RC pathological disease worse than clinical staging) [8] . There is emerging research focused on improved patient selection for cisplatinbased NAC via the use of tumour subtyping, genomics and biomarkers [18] . Such strategies might not only enhance the benefit of NAC but also avoid undue harm or futility of NAC, especially in those who are likely to be non-responders [14] [15] [16] .
Limitations of this research include the use of populationbased data that allow only limited granularity. For example, the selection of patients to undergo NAC + RC vs RC alone, as well as the selection of specific chemotherapeutic agents, could have been based on renal function, thereby introducing selection bias. Such selection bias could potentially explain the OS benefit for patients with pT2 disease who underwent NAC + RC. We performed propensity score analysis to mitigate the risk of selection bias. Furthermore, staging in the SEER-Medicare database comprises a mixture of clinical and pathological stages and, therefore, we cannot be certain of patients' initial staging prior to receiving NAC or RC. We analysed patients based on pathological stage to decrease confounding. Because clinical stage was not available, our data do not distinguish between patients who were downstaged, had no progression, or progressed during NAC from a stage less than pT2 to pT2; however, we believe that this will have had little impact as NAC is rarely used for patients with <pT2 disease.
We reported OS and CSS from time of diagnosis by transurethral resection. This method decreases lead time bias (as opposed to calculation based on time of RC), but At 5 years, the cancer specific survival is 40% in the NAC+RC group and 45% in the RC alone group. introduces immortal time bias. The 'immortal time' is the time between diagnosis and RC, through which all patients had to survive to be included. To decrease risk from immortal time bias, a landmark analysis was performed. This analysis showed no difference in OS or CSS between the two groups using 9 months after diagnosis as the landmark time.
In conclusion, we found that patients who had persistent MIBC after platinum-based NAC + RC vs RC alone derived an OS benefit but not a CSS benefit from NAC; however, this benefit is not evident in patients with persistent pT3-T4N0M0 disease. This study underscores the importance of future research investigating methods to identify patients who will respond to NAC for bladder cancer. Non-responding patients with pT2 or higher disease should be considered for adjuvant chemotherapy or immunotherapy.
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Additional supporting information may be found online in the Supporting Information section at the end of the article Table S1 . Current Procedural Terminology (CPT), International Classification of Diseases (ICD)-9 and HCPCS codes. Table S2 . Types of neoadjuvant chemotherapy. Fig. S1 . Landmark analysis at 9 months after diagnosis which estimates the time to event probabilities in NAC+RC vs RC alone group. Patients who died before the landmark time point were removed. There was no difference in overall survival between patients with stage pT2-4N0M0 undergoing NAC+RC vs RC alone.
